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Microglia, the resident immune cells of the central nervous system 
(CNS), play a pivotal role in the pathway leading to various neurodegenerative 
diseases including Alzheimer’s disease, Parkinson’s disease, prion diseases 
and HIV-dementia. Activation of microglial cells causes neurotoxicity through 
the release of a wide array of inflammatory mediators including 
proinflammatory cytokines, chemokines and reactive oxygen species. 
Microglial activation has been implicated as one of the causative factors for 
neuroinflammation in various neurodegenerative diseases. Therefore, 
suppression of microglia-mediated inflammation has been considered as an 
important therapeutic strategy for neurodegenerative diseases.  
The sphingolipid metabolic pathway plays an important role in 
inflammation, cell proliferation, survival, chemotaxis, and immunity in 
peripheral macrophages. In this study, we demonstrate that sphingosine 
kinase1 (SphK1), a key enzyme of the sphingolipid metabolic pathway, and its 
receptors are expressed in the BV2 microglial cells and SphK1 alters the 
expression and production of proinflammatory cytokines and nitric oxide in 
microglia treated with lipopolysaccharide (LPS). LPS treatment increased the 
SphK1 mRNA and protein expression in microglia as revealed by the RT-
PCR, Western blot and immunofluorescence. Suppression of SphK1 by its 
 ix 
inhibitor, N, N Dimethylsphingosine (DMS), or siRNA resulted in decreased 
mRNA expression of TNF-α, IL-1β, and iNOS and release of TNF-
α and nitric oxide (NO) in LPS-activated microglia. However, addition of 
sphingosine 1 phosphate (S1P), a breakdown product of sphingolipid 
metabolism, restored the increased expression levels of TNF-α and IL-1β and 
production of TNF-α and NO in activated microglia exposed to DMS or 
transfected with SphK1 siRNA. Hence, to summarize, suppression of SphK1 
in activated microglia inhibits the production of proinflammatory cytokines 
and NO, and the addition of S1P to microglia reverses the suppressive effects. 
Since the chronic proinflammatory cytokine production by microglia has been 
implicated in neuroinflammation, modulation of SphK1 and S1P in microglia 
could be looked upon as a future potential therapeutic method in the control of 
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1.1 The central nervous system 
The central nervous system (CNS) consists of the brain and spinal 
cord. Microscopically, the brain has around 1-2 x 1011 neurons and many more 
glial cells (namely-oligodendrocytes, astrocytes, microglia and ependymal 
cells). The glial cells are capable of dividing mitotically throughout life in 
contrast to the neurons and are derived from the ectoderm with the exception 
of the microglia, which is of monocytic lineage. The glial cells are separated 
from the neurons in the CNS by extracellular fluid by about 10-20nm 
intercellular space, which comprises about 15-20% of the brain volume. The 
glial cells do not participate in generating action potentials and have no 
synapses. The glial cells are subdivided into macroglia and microglia. The 
macroglia consist of the astrocytes and oligodendrocytes (Noback, 2005). 
1.2 Microglia: history and types 
Microglial cells were first described by Franz Nissil (Nissil, 1899) as 
rod cells, whose function was considered to be similar to leukocytes. Ramon 
Y Cajal (Cajal, 1913) described microglial cells as the ‘third element’ of the 
CNS, which refers to a group of cells that are morphologically distinct from 
the first and second elements, namely neurons and astrocytes. Del Rio-
Hortega (P. Río-Hortega, 1920) differentiated this third element into microglia 
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and oligodendrocytes and was also the first to describe the two types of 
microglia: amoeboid and ramified. 
Microglia, comprising 10-20% of the total glial cell population of the 
CNS, are the resident macrophage cells within the entire neuroaxis and 
represent the primary immunocompetent cells that protect against invasions by 
various routes, be it infectious agents or tumours. True to their macrophage 
nature, they also remove cellular debris from within the CNS. Thus they act as 
vigilant guardians of the brain and spinal cord. Although similar to peripheral 
macrophages, they possess distinguishing electrophysiological and 
biochemical properties, which make microglia different from the macrophages 
(Squire, 2008). 
Microglia contain lysosomes and vesicles characteristic of 
macrophages, a sparse endoplasmic reticulum and a few cytoskeletal fibers 
(Squire, 2008). They usually have small rod shaped somas from which 
numerous processes extend (Squire, 2008). Processes from different microglia 
rarely overlap or touch (Squire, 2008). They are found in the CNS within the 
parenchyma (parenchymal microglia), and in the circumventricular organs.  
Microglia exist in different morphological and functional forms 
(Noback, 2005): 
• Resting ramified microglia: They are known as the resident brain 
macrophages and found in the normal adult CNS. They have finely 
branched and ramified processes (Noback, 2005).  
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• Activated amoeboid or reactive nonphagocytic microglia: They are 
found in areas of secondary reaction as in nerve transection and in 
CNS inflammation and are capable of producing cytokines (Noback, 
2005). 
• Phagocytic microglia or reactive phagocytic microglia: They are found 
in areas of trauma, infection and neuronal degeneration (Noback, 
2005). 
1.3 Origins of microglia 
Microglia are of myelomonocytic lineage and are derived from 
hemangioblastic mesoderm. They become part of the CNS parenchyma during 
early embryonic development around the time when neurulation is completed 
(Streit, 2001). The fetal macrophages (Takahashi, et al., 1989) are known to 
populate the developing neuroectoderm as early as the 8th embryonic day in 
rodents (Alliot, et al., 1999). These fetal macrophages are considered to be the 
earliest detectable microglial precursor cells. With the further development of 
the CNS in the embryo, the fetal macrophages change from their rounded 
shape to embryonic microglia, which have short processes. At the perinatal 
stage, the embryonic microglia change into amoeboid microglia and these 
cluster around the supraventricular corpus callosum (Hurley, et al., 1999, Ling 
and Wong, 1993). The amoeboid microglia persist in the corpus callosum for 
the first two postnatal weeks, migrate into the cerebral cortex and differentiate 
into fully ramified microglia. A few microglia may also be replaced by 
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perivascular (space around the medium and small sized cerebral vessels) cells 
which are mononuclear phagocytes, replaced continuously by bone marrow 
progenitors (Hickey and Kimura, 1988), 
1.4 Functions of microglia 
Microglia are involved in clearance of apoptotic cells (Polazzi and 
Contestabile, 2002) during brain remodeling in embryogenesis and also brain 
remodeling through their assistant role in synapse stripping and matrix 
reorganization (Harry and Kraft, 2008). They also participate in the induction 
of neuronal death in cerebellum during normal development (Marin-Teva, et 
al., 2004). In the adult brain, microglia are in intimate contact with neurons 
and serve important maintenance functions and are capable of responding to 
subtle changes in the microenvironment, (Alemany, et al., 2007, Davalos, et 
al., 2005, Kreutzberg, 1996, Nimmerjahn, et al., 2005, Raivich, 2005) These 
cells play a major role in phagocytosis and clearance of aberrant or excess 
proteins e.g. β amyloid (Harry and Kraft, 2008). 
  In the CNS injury, microglia actively monitor and control the 
extracellular environment, walling off areas of the CNS from non-CNS tissue, 
and remove degenerating and dysfunctional cells (Harry and Kraft, 2008). The 
activated microglia in response to CNS inflammation secrete pro-
inflammatory cytokines such as TNF-α and IL-1β and serve as antigen 
presenting cells (Carson, et al., 1998, Carson and Sutcliffe, 1999, Frei and 
Fontana, 1997, Hickey and Kimura, 1988) Increases in TNF-α and IL-1β have 
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been observed prior to neuronal death (Harry, et al., 2008, Lefebvre 
d'Hellencourt and Harry, 2005, Matusevicius, et al., 1996) and recent studies 
suggest that the activation of pro-inflammatory factors such as TNF-α can 
participate in causation of neuronal death (Harry and Kraft, 2008, Harry, et al., 
2008, Kaushal and Schlichter, 2008). In adddtion, microglia produce multiple 
secreted factors including pro- and anti-inflammatory cytokines, nitric oxide, 
reactive oxygen species (ROS), glutamate, and growth factors (Harry and 
Kraft, 2008). Microglia also express the glutamate transporter, GLT-1 and, 
thus, may provide a level of protection through the elimination of extracellular 
glutamate (Nakajima, et al., 2001). Microglia can facilitate the apoptosis and 
phagocytosis of infiltrating T cells through various signaling pathways leading 
to a subsequent down regulation of microglial immune activation (Magnus, et 
al., 2002) 
 Ageing leads to neurodegeneration which might not only be due to a 
loss of neuroprotective properties, but also the actual loss of microglia (Ma, et 
al., 2003). This loss of microglia in senescence appeared to be caused by 
increased intracellular accumulation of iron leading to intracellular oxidative 
damage (Streit, et al., 2008). 
          The mechanisms by which the myriad functions and actions of 
microglia take place need to be studied in order to understand and apply it in 
possible therapeutic modulations. Hence in vitro studies are conducted by 
activating microglia by various stimuli such as LPS, β-amyloid, and IFN-γ, 
thrombin and proinflammatory cytokines. LPS, which is an endotoxin, is one 
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of the components of the outer membrane of gram negative bacteria and is an 
activator of microglia. LPS has been shown to activate the microglia by 
crossing the blood-brain barrier (BBB) in areas of loss of structural integrity 
of the BBB. Such an activation of microglia leads to the expression of 
proinflammatory cytokines, chemokines and reactive oxygen species that 
modulate inflammation. The endogenous receptor CD14 on microglial cells is 
the target for the LPS (Rivest, 2003). 
            β-amyloid which are present in neurofibrillary tangles and senile 
plaque in the brain of Alzheimer’s disease patients, are known to be 
surrounded by reactive microglia indicating its potential role in the disease 
process (Dheen, 2007). Microglia activated by β-amyloid have been known to 
express proinflammatory cytokines and chemokines such as IL-1β, IL-8, IL-
10, IL-12, TNF-α etc (Dheen, 2007). 
           IFN-γ is another known activator of microglial cells and serves 
important functions in innate and adaptive immunity (Dheen, 2007). Microglia 
in murine models show significantly increased myelin phagocytosis, 




Lipids account for approximately 10% of the weight of the wet brain 
and half the dry matter of the brain (Sastry, 1985). The complex lipids are of 
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two types- glycerolipids and sphingolipids. The sphingolipids contain the long 
chain amino alcohol, sphingosine. The sphingolipids are derived from 
ceramide, which occurs in large concentrations in the nervous tissue and they 
include sphingomyelins, cerebrosides, sulfatides and gangliosides (Sastry, 
1985).  
  Sphingomyelin accounts for 4.2-12.5% of the phospholipid content of 
the brain in various species. The peripheral nerves and the white matter have a 
higher concentration of sphingomyelin which forms a major component of 
myelin membrane (Sastry, 1985).  
The production and metabolism of sphingolipids occur via de novo 
synthesis and the salvage pathway. The endoplasmic reticulum is the site for 
the de novo synthesis of sphingolipids. Palmitoyl CoA and serine get 
condensed to form 3-ketosphinganine in the presence of the catalytic action of 
serine palmitoyl transferase. Next, the 3-ketosphinganine is then reduced by a 
NADH dependant reductase to produce dihydrosphingosine. Ceramide 
synthase then adds different lengths of acyl chains to produce 
dihydroceramide (Ogretmen and Hannun, 2004). This is subsequently 
desaturated via dihydroceramide desaturase to form ceramide. Ceramide is 
then phosphorylated by ceramide kinase to ceramide-1-phosphate which is a 
bioactive sphingolipid. After ceramide formation, the remaining reactions 
occur in the Golgi apparatus and result in the incorporation of ceramide into 
glycolipids and sphingomyelin. Sphingolipids can also be recycled and 
ceramide can be produced by the salvage pathway, in which 
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glucocerebrosidase and sphingomyelinase breakdown various membrane 
glycolipids and sphingolipids. Ceramidases remove acyl chain from ceramide 
substrates and form sphingosine. Sphingosine can be recycled back to 
ceramide via ceramide synthases or, sphingosine can be phosphorylated to 
sphingosine-1-phosphate (S1P) by sphingosine kinases (Hannun and Obeid, 
2008, Olivera, et al., 1998). S1P is dephosphorylated by sphingosine-1-
phosphate phosphatase to form sphingosine. The final step in the biosynthesis 
is the irreversible cleavage of S1P into ethanolamine phosphate and 
hexadecenal by S1P lyase (Snider, et al., 2010).  
Of all the products of sphingolipid synthesis, ceramide, sphingosine and 
S1P have been established in cell signaling roles. Ceramide has an important 
role in cellular stress responses such as cell cycle arrest, serum and nutrient 
deprivation, terminal differentiation, apoptosis and cell senescence (Hannun 
and Obeid, 2008). It has also been implicated in inflammation and skin 
homeostasis (Snider, et al., 2010). The action of ceramide on inflammation 
can be mediated by one of its phosphorylated products ceramide-1-phosphate, 
which activates phospholipase A2 (Nakamura, et al., 2006). In addition, 
ceramide-1-phosphate is required for the membrane translocation of 
phospholipaseA2 and downstream production of PGE2 (Lamour, et al., 2009) 
Upon the degradation of ceramide, to sphingosine, S1P is rapidly 
formed via phosphorylation which then binds to G protein coupled receptors 
(S1P receptors). S1P has been implicated in myriad cell signaling pathways 
such as angiogenesis, cell migration and movement, cell survival and 
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proliferation, cellular architecture, cellular contacts and adhesions, heart 
development, vascular development, atherogenesis, acute lung injury and 
acute respiratory distress, tumourogenecity, metastasis, inflammation and 
immunity (Alemany, et al., 2007, Hait, et al., 2006).  
 
1.6   Sphingosine kinases 
1.6.1  Types and Location  
Two isoforms of SphKs have been characterized so far: SphK1 and 
SphK2. In humans, SphK1 is located on chromosome 17 and SphK2 is located 
on chromosome 19 (Bryan, et al., 2008). SphK1 is present in the cytosol 
(Kohama, et al., 1998) and unlike Sphk1, the localization of SphK2 is cell type 
specific (Okada, et al., 2005, Sankala, et al., 2007). Both of the kinases 
phosphorylate erythro-sphingosine (Sphingosine), dihydrosphingosine and 
phytosphingosine, which are key sphingolipids (Melendez, 2008). In adult 
mouse, SphK1 is present abundantly in the spleen, heart, lung and brain, 
whereas SphK2 is expressed in the brain, kidney and the liver (Liu, et al., 
2000). SphK1 translocates from the cytosol to the membrane periphery where 
it phosphorylates sphingosine into S1P. Sphk1 translocation to the plasma 
membrane has been shown to be facilitated by calcium and integrin binding 
protein1 (Jarman, et al., 2010). Another possible mechanism for this 
translocation is via TNF-α by the means of phospholipase D1 dependant 
mechanism in monocytes (Sethu, et al., 2008)  
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Many proteins affecting the activity of SphK1 have emerged, which 
include D-catenin/neural plakophilin- related armadillo repeat protein (Fujita, 
et al., 2004), aminoacyclase 1(Maceyka, et al., 2004), eukaryotic elongation 
factor 1A (Leclercq, et al., 2008), filamin A (Maceyka, et al., 2008), 
sphingosine kinase 1-interacting protein (Lacana, et al., 2002), and platelet 
endothelial adhesion molecule-1 (Fukuda, et al., 2004). Protein phosphatase 
2A has been shown to deactivate SphK1 (Barr, et al., 2008) and cytosolic 
chaperonin containing TCP-1 has been shown to mediate proper folding of 
SphK1 (Zebol, et al., 2009) 
Another mechanism of regulation of SphK1 is at the transcriptional 
level, where the SphK1 promoter was shown to be up regulated in response to 
LPS in RAW macrophages leading to possible protection from apoptosis 
(Hammad, et al., 2006). Hypoxia inducible factor 2α has also been shown to 
upregulate SphK1 expression selectively in glial cells, thereby leading to S1P 
secretion and enhancement of transcellular angiogenesis (Anelli, et al., 2008). 
Exposure of SphK1 to DNA damage, TNFα and proteolysis causes its 
downregulation (Taha, et al., 2004). 
1.6.2  Activation of SphKs  
The SphKs have been shown to be activated by various factors 
including (Bryan, et al., 2008): (a) Growth factors -platelet derived growth 
factor, epidermal growth factor, vascular endothelial growth factor, nerve 
growth factor, basic fibroblast growth factor, transforming growth factor β, 
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and insulin like growth factor-1; (b) Cytokines: TNF-α, interleukins; (c) 
Hormones: prolactin and estradiol; (d) Hypoxia, and (e) Histamine. 
1.6.3  Functions of SphK1 and S1P 
The cellular levels of sphingosine, ceramide and S1P and the 
activation/inactivation of SphK1 play major roles in myriad biological 
processes. S1P is known to be a modulator of cell proliferation, survival, 
apoptosis, migration, and Ca+2 hemostasis (Alemany, et al., 2007).  
S1P can act intracellularly as a second messenger and extracellularly 
as a ligand for G-Protein coupled receptors coded by endothelial 
differentiation genes and are known as S1P receptors (S1P1, S1P2, S1P3, 
S1P4, S1P5) (Ozaki, et al., 2003, Rosen and Goetzl, 2005) thereby modulating 
cellular processes including proliferation, stimulation of adherent junctions, 
enhanced extracellular matrix assembly, formation of actin stress fibers and 
inhibition of apoptosis induced by ceramide or growth factor withdrawal 
(Alvarez, et al., 2007, Melendez, 2008) . The modulations of these functions 
have been studied in peripheral macrophages and other immune cells (Gude, 
et al., 2008, Hammad, et al., 2008, Melendez, 2008).  
S1P1 signaling is known to be essential for embryonic blood vessel 
development (Liu, et al., 2000). S1P has also been shown to elicit egress of 
lymphocytes into the blood in an S1P1 dependant manner. S1P2 and S1P3 
activate phospholipase-C and Rho and the knockout of both these receptors in 
mice decreases litter size and survival rates (Ishii, et al., 2002). Although not 
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studied extensively, S1P4 is known to be expressed in lymphocytes and is 
therefore involved in T-cell proliferation (Wang, et al., 2005). S1P5 is 
expressed in dendritic and natural killer cells (Walzer, et al., 2007). Activation 
of S1P receptors also takes place via growth factors such as platelet derived 
growth factor, which activates SphK1 and thus activating S1P receptors 
(Olivera and Spiegel, 1993). 
The differences in the actions of the various S1P receptors are of 
important consequence in the CNS. Neurite extension and retraction are 
important in CNS development and is regulated by contrasting actions of Rho 
and Rac, which control the actin cytoskeleton (Li, et al., 2002). Upon 
activation of S1P1 by S1P, there is upregulation of Rac which is required for 
neurite outgrowth (Estrach, et al., 2002). In contrast, when S1P2 is activated 
by S1P, it upregulates Rho, which induces collapse of growth cones and 
inhibition of neurite outgrowth (Nakamura, et al., 2002). Also, glial cell line 
derived neurotrophic factor transactivates SphK/S1P signaling and induces 
neurite extension via S1P1 (Murakami, et al., 2007). 
S1P1 is expressed prominently in cerebral cortical proliferative zone 
and in ventricular areas of mesenchephalon and coincides with the period of 
neurogenesis (McGiffert, et al., 2002). When neural stem cells are exposed to 
S1P, they differentiate into neurons and astrocytes (Harada, et al., 2004). 
Therefore S1P receptors and S1P play a very important role in neurogenesis.  
Apoptosis in neural cells is essential for establishing functional neural 
populations and to eliminate defective neurons.  Ceramide in low 
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concentrations maintains the immature hippocampal neurons and promotes 
cell death in ageing hippocampal neurons while in high concentrations 
ceramide causes cell death (Mitoma, et al., 1998). Hence S1P is required for 
the remodeling of the developing brain into the functional adult brain. S1P by 
itself can lead to the release of glutamate from the hippocampus (Kajimoto, et 
al., 2007).  All these studies suggest that S1P may be linked to memory 
formation in the brain since the hippocampus is the site of memory and the 
remodeling of brain is the basis for functional connections between neurons 
essential for memory formation. In neurodegenerative diseases like 
Alzheimer’s, the memory loss could therefore be attributed to the actions of 
S1P and the sphingolipid pathway.  
S1P receptor expression is not the only determinant of S1P activity. 
S1P exists in high levels in plasma (Caligan, et al., 2000) and is found in low 
levels in tissues (Edsall, et al., 2000). This S1P gradient is important in the 
homing of immune cells to the site of inflammation since S1P levels are high 
in inflammatory conditions (Rivera, et al., 2008). Serum S1P levels are also 
higher than plasma levels (Yatomi, et al., 1997) due to the release of S1P from 
platelets during the blood clotting and in the presence of thrombin (Yatomi, et 
al., 1997). Red blood cells and vascular endothelial cells are also considered 
important sources of S1P in plasma (Jessup, 2008). 
The actions of S1P are considered to be a consequence of intracellular 
production, export to extracellular space, and activation of S1P receptors. The 
SphK1 and S1P pathway is a complex one, with crossing over with G protein 
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coupled receptor and receptor tyrosine kinase pathways. Generally, S1P is 
considered important for growth and survival, whereas sphingosine and 
ceramide are associated with cell growth arrest and apoptosis (Ogretmen and 
Hannun, 2004). Therefore the balance between ceramide and sphingosine 
versus S1P could be the determinant of cell growth and survival (Spiegel and 
Milstien, 2003). SphK1 is the enzyme that leads to the production of S1P from 
sphingosine and ceramide, and is therefore critical in the balance between 
ceramide/sphingosine and S1P. 
 It has been found that SphK1 plays a role in activation of immune 
cells and also in chemotaxis and wound healing (Melendez, 2008). SphK1 has 
been reported to be involved in LPS and TNF-α mediated inflammatory 
processes (Hammad, et al., 2008, Melendez, 2008) in immune cells.  
1.6.4  Clinical significances of sphingolipid pathways 
The many functions and roles of the sphingolipid pathway are being 
studied with interest.  The roles discovered range from that of metabolism, 
tumour formation, inflammation, signaling pathways, absorption and 
transport, to receptor function for viruses and bacteria (Duan and Nilsson, 
2009).   
Sphingolipid pathways have been implicated also in myriad other 
diseases such as asthma, inflammatory bowel disease, colon carcinogenesis, 
and rheumatoid arthritis. In asthma, SphK1 and S1P regulate many processes 
of the asthmatic attack. Mast cell degranulation and migration is dependant on 
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the transactivation of S1P2 receptor which regulates the antigen binding to its 
receptor (Jolly, et al., 2004). S1P induces airway smooth muscle contraction 
(Rosenfeldt, et al., 2003) and also influences eosinophil migration (Roviezzo, 
et al., 2004). 
Rheumatoid arthritis is a chronic autoimmune disease involving 
inflammation of joints resulting in debilitating pain and deformities. The most 
recent therapeutic strategies target TNF-α. TNF-α activates SphK1 leading to 
production of S1P in rheumatoid arthritis patients. S1P causes proliferation 
and cytokine production in the synovial cells of the joints (Kitano, et al., 
2006). Also, S1P is elevated in the synovium of these patients (Lai, et al., 
2008). These findings suggest that S1P indeed plays an important role in 
rheumatoid arthritis. 
Inflammatory bowel disease is characterized by inflammation of the 
intestines as the name suggests and malabsorption of nutrients. It has been 
treated with various modalities, immmunosuppression and steroids being the 
main modality. TNF-α has been implicated in the disease process also and 
since it is known to activate SphK1, the sphingolipid pathway is of importance 
in this disease process (Pettus, et al., 2003, Sethu, et al., 2008). 
 In the CNS, the sphingolipid pathway has been shown to play a key 
role in neuron specific functions such as regulation of neurotransmitter release 
and proliferation and survival of neurons and glia (Okada, et al., 2009).  
S1P receptors play an important role in autoimmune diseases such as 
multiple sclerosis. This has come to light from studies conducted with the drug 
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fingolimod (FTY720). Multiple sclerosis is and autoimmune disease where T-
cells migrate across BBB and attack myelin in the CNS. This leads to 
demyelination, axonal damage and the resultant clinical picture of multiple 
sclerosis which is that of loss of optimal function of the skeletal muscles due 
to nerve damage and also includes loss of vision.  FTY720 is a pro-drug which 
is converted into an S1P mimetic by the action of SphK2, which leads to 
internalization and degradation of the S1P receptor and also its prolonged 
downregulation (Matloubian, et al., 2004). Therefore the signal given by S1P 
for the migration of immune cells is no longer present, and this in theory could 
help reduce the progression of multiple sclerosis. Indeed, the results of a phase 
2 randomized double blind placebo controlled clinical trial evaluating FTY720 
in the treatment of multiple sclerosis shows that the relapse rate of the treated 
group was significantly lower than the placebo group (Kappos, et al., 2006). 
Such clinically relevant results are very promising in the role of S1P in future 
treatment modalities. 
The part that the sphingolipids play in inflammation as discussed 
earlier, is particularly interesting, since many neurodegenerative conditions 
such as Alzheimer’s disease find their origin or progression due to 
inflammation. Therefore, the sphingolipid pathway modulation may become a 




1.7 Aims and hypothesis of this study  
1.7.1 Aims of this study 
Microglial activation in response to inflammatory stimuli is considered 
to be the hallmark in neurodegenerative diseases of the CNS. In the normal 
state, microglia act as scavengers of the CNS by removing damaged cells. But 
the chronic stimulation of microglia causes production of proinflammatory 
chemokines and cytokines such as TNF-α leading to further neuronal damage 
rather than just a scavenging action. Hence the modulation of microglia by 
various involved pathways is considered to be an important step in preventing 
neurodegenerative disease progression.   
 It has been reported that secretion of TNF-α, a proinflammatory 
cytokine is reduced with inhibition of SphK1 (Niwa, et al., 2000) which is 
present in abundance in the CNS as a major component of the lipid 
membranes. TNF-α  secreted by activated microglia has been shown to be 
involved in neuroinflammation (Block and Hong, 2005, Dheen, et al., 2007). 
Hence, the modulation of TNF-α levels could form a potential therapeutic 
basis for the treatment of neuroinflammatory conditions. Due to the 
similarities between immune cells and microglia, it is therefore quite likely 
that SphK1 and S1P would play significant roles in microglial activation. The 
purpose of this study was therefore to understand the interactions between the 
sphingolipid pathway and activated microglia and also the effects on 
proinflammatory cytokine production by activated microglia of DMS, a 
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methylated derivative of sphingosine and a known inhibitor of SphK1. To 
address this, 
• The presence of SphK1 and S1P receptors on microglia was confirmed 
• The effect of activation of microglia on SphK1 was investigated 
• The effects of suppression of SphK1 by SiRNA on the production of 
proinflammatory cytokines were determined.  
• DMS, a methylated derivative of sphingosine and a known chemical 
inhibitor of SphK1 was used to confirm the effects on proinflammatory 
cytokines. 
• S1P was exogenously administered to evaluate its pro/anti inflammatory 
effects on activated microglia. 
 
1.7.2  Hypothesis 
Modulation of SphK1 in resting and activated microglia regulates the 






























2.1 Cell culture 
BV2, a murine microglial cell line, which is a suitable model for in 
vitro study of microglia (Bocchini, et al., 1992) was used in this study.  
2.1.1 Materials 
 
Trypsin-EDTA (X0930, TE, Biowest France) 
Fetal bovine serum (SV30160.03, FBS HyClone, Utah, USA) 
Dulbecco’s modified eagle’s medium (D1152, DMEM, NUMI Sigma, USA) 
Antibiotic antimycotic cocktail (A5955, Sigma, USA) 
75cm2 tissue culture flasks (NUNC, Denmark) 
2.1.2 Procedure 
 
The cells were grown in a 75cm2 treated flask and washed with 
phosphate buffered saline solution (PBS) twice and then treated with Trypsin-
EDTA in PBS for 3minutes at 37° C. The TE was inactivated by equal volume 
of 1x FBS. The solution was centrifuged at 1000rpm at 4° C for 5 min. The 
supernatant was discarded and the pellet was resuspended in 10 ml of DMEM 
containing 10 % FBS and 1 % antibiotic antimycotic cocktail (10 % medium). 
The cells were counted using a hematocytometer and approximately 
2x106cells were plated into each flask containing 10 ml of 10 % FBS in 
DMEM and grown at 37° C and 5 % CO2 in an incubator. The cells were 
subcultured every 2-3 days. For experiments, the BV2 cells were maintained 
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in DMEM without antibiotics or FBS for the required periods of treatment 
(Basic medium). For extraction of RNA and protein, 2x106 cells were plated 
into cell culture dishes. For siRNA treatment and immunofluorescence, 
2x105cells were used per well in a 6 well plate or 24 well plate respectively. 
2.2 Treatment of cell culture  
2.2.1 Materials 
 
LPS (L6529, Sigma, USA) 
N, N Dimethylsphingosine -DMS (310500, Calbiochem, Germany) 
Sphingosine-1-phosphate- S1P (S9666, Sigma, USA) 
Fetal bovine serum (SV30160.03, FBS HyClone, Utah, USA) 
2.2.2 Procedure 
 
Cells were plated onto cell culture dishes and grown in 10 % 
DMEM/FBS with antibiotics overnight.  The following day, medium was 
discarded and washed twice with PBS.  The cells were grown in basic medium 
and treated with LPS (1 µg/ml), DMS (10 µM) and with S1P (10 nM) in 
various experimental combinations for different time points (30 min, 1 h, 3 h, 
6 h) in the incubator. The control was taken as cells grown in basic medium 
for the same time periods. The medium was then discarded and washed twice 
with ice cold PBS and the cells and supernatant were used for extraction of 
RNA, protein, ELISA, immunofluorescence etc. 
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2.3 RNA extraction & Reverse transcription 
polymerase chain reaction (RT-PCR) 
2.3.1 Principles 
2.3.1.1 RNA extraction 
 
The RNA extraction procedure combines the selective binding 
properties of a silica-based membrane with the speed of microspin technology. 
Nucleic acids, either DNA or RNA, are adsorbed onto the silica-gel membrane 
in the presence of chaotropic salts, which remove water from hydrated 
molecules in solution. Polysaccharides and proteins do not adsorb and are 
removed. A specialized high-salt buffer system allows upto 100 µg of RNA 
longer than 200 bases to bind to the silica membrane. 
 
Structure of silica gel used for RNA extraction. (adapted from-
http://www1.qiagen.com/resources/info/qiagen_purification_technologies_1.a
spx#structure) 
Biological samples are first lysed and homogenized in the presence of 
a highly denaturing guanidine-thiocyanate–containing buffer, which 
immediately inactivates RNases to ensure purification of intact RNA. Ethanol 
is added to provide appropriate binding conditions, and the sample is then 
applied to a spin column, where the total RNA binds to the membrane and 
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contaminants are efficiently washed away. After a wash step, pure nucleic 
acids are eluted under low- or no-salt conditions in small volumes. High-




Polymerase chain reaction (PCR) is a method that allows exponential 
amplification of short DNA sequences (usually 100 to 600 bases) within a 
longer double stranded DNA molecule. PCR entails the use of a pair of 
primers, each about 20 nucleotides in length that are complementary to a 
defined sequence on each of the two strands of the DNA. These primers are 
extended by a DNA polymerase so that a copy is made of the designated 
sequence. After making this copy, the same primers can be used again, not 
only to make another copy of the input DNA strand but also of the short copy 
made in the first round of synthesis. This leads to logarithmic amplification. 
Since it is necessary to raise the temperature to separate the two strands of the 
double strand DNA in each round of the amplification process, a major step 
forward was the discovery of a thermo-stable DNA polymerase (Taq 
polymerase) that was isolated from Thermus aquaticus, a bacterium that grows 
in hot pools; as a result it is not necessary to add new polymerase in every 
round of amplification.  
Real time PCR or quantitative PCR is a variation of the standard PCR 
technique used to quantify DNA or messenger RNA (mRNA) in a sample. 
 25 
Using sequence specific primers, the relative number of copies of a particular 
DNA or RNA sequence can be determined. The term relative is used since this 
technique tends to be used to compare relative copy numbers between tissues, 
organisms, or different genes relative to a specific housekeeping gene. The 
quantification arises by measuring the amount of amplified product at each 
stage during the PCR cycle. DNA/RNA from genes with higher copy numbers 
will appear after fewer melting, annealing, extension PCR cycles. 
Quantification of amplified product is obtained using fluorescent probes and 
specialized machines that measure fluorescence while performing temperature 
changes needed for the PCR cycles. SYBR green is a dye that binds to double 
stranded DNA but not to single-stranded DNA and is frequently used in real-
time PCR reactions. When it is bound to double stranded DNA it fluoresces 
very brightly. During extension, increasing amount of dye binds to the newly 
formed double-stranded DNA, resulting in an increase in the fluorescence 
signal. Thus, the fluorescence measurement performed at the end of the 
extension step of every PCR cycle reflects the increasing amount of amplified 
DNA. After a few cycles, the fluorescent signal is first recorded as statistically 
significant above background signal. This point is described as threshold cycle 
(Ct), which occurs during the exponential phase of amplification (Gibson, et 
al., 1996).In addition, the specificity of the amplification and PCR product 
verification can be achieved by a melting curve of the PCR product (Ririe, et 
al., 1997). 
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  After several (often about 40) rounds of amplification, the PCR 
product is analyzed on an agarose gel and is abundant enough to be detected 
with an ethidium bromide stain. In order to measure messenger RNA 
(mRNA), the method was extended using reverse transcriptase to convert 
mRNA into complementary DNA (cDNA), which was then amplified by PCR 
and, again analyzed by agarose gel electrophoresis.  
Thus the steps involved in RT-PCR can be enumerated as follows: 
1. mRNA is copied to cDNA by reverse transcriptase that has an endo H 
activity， using an oligo dT primer. This removes the mRNA allowing 
the second strand of DNA to be formed.  
2. Denaturation ：cDNA is denatured at more than 90 degrees (~94 
degrees) so that the two strands separate. 
3. Annealing：The sample is cooled to 50 to 60 degrees and specific 
primers are annealed that are complementary to a site on each strand. 
The primers sites may be up to 600 bases apart but are often about 100 
bases apart, especially when real-time PCR is used. 
4. The temperature is raised to 72 degrees and the heat-stable Taq DNA 
polymerase extends the DNA from the primers.  
5. After 30 to 40 rounds of synthesis of cDNA, the reaction products are 
analyzed by agarose gel electrophoresis. The gel is stained with 
ethidium bromide 
Using the 2-∆∆Ct method (Livak and Schmittgen, 2001).  The data are 
represented as the fold change of target gene expression normalized to an 
endogenous reference gene, relative to a calibrator. For the treated samples, 
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evaluation of 2-∆∆Ct indicates the fold change of gene expression relative to 
the untreated control. For this method to be valid, the amplification 
efficiencies of the target and reference must be approximately equal. 
2.3.2 Materials 
 
Qiagen RNeasy mini kit (74106, Qiagen, Germany) 
M-MLV Reverse transcriptase (M170A, Promega, Madison, USA) 
Oligo (dT) 15 primer (c110A, Promega, Madison, USA) 
dNTP mix (U1240, Promega, Madison, USA)  
RNasin -RNase inhibitor (Promega, USA, Cat. No. N2111,) 
LightCycler Fast Start DNA master plus SYBR Green 1 kit (03515885001, 
Roche Mannheim, Germany) 
TAE buffer (Invitrogen, USA, Cat. No. 15558034) 
100bp DNA step ladder (Promega, USA, Cat. No. G6951) 
LightCycler instrument (Roche Molecular Biochemicals) 
GeneGenius (Syngene, UK) 
Spectrophotometer (Eppendorf, Germany) 
2.3.3 Procedure 
2.3.3.1 RNA extraction procedure from BV2 cells 
 
Total RNA from BV2 microglial cells subjected to various treatments 
was extracted as per the instructions given by the Qiagen RNeasy mini kit. 
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Approximately, 1×106 cells were used to extract total RNA. Cells were lysed 
in 650 µl of RLT buffer (containing a highly denatured guanidine 
isothiocyanate which inactivates RNase) and then scraped from the flask with 
the scraper. The lysate was homogenized, then centrifuged for 30s at 14000g 
in a microfuge and the supernatant was mixed with 650 µl of 70 % ethanol to 
clear lysate. The sample was applied to an RNeasy mini spin column (silica-
gel membrane, maximum binding capacity is 100 µg of RNA longer than 200 
bases) and spun for 30 sec at 14000g and then flow-through was discarded. 
The RNA bound to the membrane was washed with buffer RW1 and RPE 
sequentially. High-quality RNA was then eluted in 20 µl of RNase free water. 
The concentration and purity of the extracted RNA was evaluated 
spectrophotometrically at 260 and 280 nm (Biophotometer, Eppendorf, 
Germany). The RNA samples were stored at -80° C until experiments. 
2.3.3.2 Procedure for cDNA synthesis 
 
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT) 
is an RNAdependent DNA polymerase that is used for first-strand synthesis of 
cDNA from RNA molecules. 2 µg of RNA was mixed with 2 µl of Oligo (dT) 
15 and incubated at 70° C for 5 min. Each sample was then made to a final 
volume of 25 µl on ice with the following regents: 1 µl of M-MLV Reverse 
transcriptase, 5 µl of M-MLV RT 5x buffer ，0.7 µl of RNasin, 0.5  µl. of 
dNTP mix and nuclease free water and incubated at 42° C for 60 min and 70° 
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C for 10 min. The cDNA thus obtained was then diluted 3 times in sterile 
water and stored at -20° C. 
2.3.3.3 Procedure for real time polymerase chain reaction (RT-PCR) 
 
RT-PCR was carried out using LightCycler Fast Start DNA master 
plus SYBR Green 1 kit as per the manufacturer’s instructions. The 
oligonucleotide primer sequences used are tabulated below. The primer 
sequences used for the S1P receptors were derived from (Kimura, et al., 
2008): 
Table 1: Primer sequences used 
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  2.5 µl of cDNA was used per sample. Each sample was run with a 
corresponding internal control, β actin. After pre incubation at 95˚ C for 10 
min, the PCR was performed as follows: 35-45 cycles of denaturation at 95˚ C 
for 5 sec, annealing at   60˚ C for 5 sec, and elongation at 72˚ C for PCR 
product size per 25 sec. The crossing points (the cycle number at which the 
Lightcycler detected the upstroke of the exponential phase of PCR product 
formation) were taken normalized with β actin for each sample. Statistical 
significance was estimated using Student’s t-test and the fold change was 
calculated using the 2-{∆∆Ct} method (Livak and Schmittgen, 2001).  
2.4 Western immunoblot assay 
2.4.1 Principles 
 
Protein expression analysis is a very important tool of modern 
molecular biology. One key approach to explore protein expression is to 
analyze them by electrophoresis. SDS-PAGE (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis), was developed in the mid 1960s, and is 
widely used to separate proteins according to their net charge, size and shape. 
During electrophoresis, SDS serves to denature proteins by binding to 
hydrophobic regions of proteins and causes them to unfold into extended 
polypeptide chains, thus becoming dissociated from other proteins and freely 
soluble in the SDS solution (β-mercaptoethanol is also used to break the S-S 
bonds in proteins). The negatively charged SDS also wraps the proteins and 
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makes them negatively charged and thus the proteins move through the gel 
matrix towards the positive electrode .The movement is inversely proportional 
to the log of their molecular weight (William Wu, 2003).  
Western Blotting is a procedure in which different types of proteins are 
separated by SDS-PAGE and then immobilized onto a solid support PVDF 
(polyvinlylidene difluoride) or nitrocellulose membrane. The protein of 
interest is then detected by incubating the membrane with a specific antibody 
probe. Thus a standard western blot involves 4 steps: 
• separation of proteins by SDS-PAGE 
• transfer of proteins onto a solid membrane 
• incubation of the membrane with specific antibodies  
• detection of hybridized signals 
2.4.2 Materials 
 
Protein extraction kit (78501, Pierce, IL, USA) 
Protease inhibitor cocktail kit (78410, HaltTM, IL, USA) 
Protein assay kit (500-0007, Bio-Rad, California, USA) 
Μouse anti β actin Abcam ab18061, Cambridge, USA,  
Rabbit polyclonal SphK1 ABGENT AP7237c, San Diego, USA 
Horseradish peroxide conjugated goat anti rabbit secondary antibody (7074, 
Cell Signaling Technology, Boston, MA, USA) 
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Enhanced chemiluminescence detection system (34095, Thermo scientific, 
Supersignal West Femto maximum Sensitivity Substrate) 
Stripping buffer (0021059, Pierce, IL, USA) 
Quantity One Software (Bio-Rad, version 4.4.1, California, USA). 
 
 
Table 2: Reagents used for Western Blotting 
10% resolving gel: 
H2O  
30% acrylamide mix  
1.5 M Tris (pH 8.8)  
10% SDS  












5% stacking gel:  
 
H2O  
30% acrylamide mix  
1.0 M Tris (pH 6.8)  
2.0 10% SDS  












1x SDS gel-loading buffer:  
50mM Tris.Cl (pH 6.8) 
100mM dithiothreitol 
2% SDS 
0.1% bromophenol blue 
10% glycerol 
 










1X TBS:  
Tris base  
NaCl  
H2O up to 1 liter; adjusted to pH 7.6 with 2N HCl 
2.42 g 
0.8 g 
1X TBST:  
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1X TBS 1 liter 





Protein extracts were made from BV2 cells subjected to different 
treatment conditions using protein extraction kit and protease inhibitor 
cocktail kit and were quantified using protein assay kit. 20 µg of each protein 
sample was separated on 10 % SDS-polyacrylamide gel and transferred to 
polyvinylidene difluoride transfer membrane. The membranes were blocked 
with 5 % non-fat dry milk for 1h and incubated with primary antibodies 
according to manufacturer’s recommendations (1:10,000 for β actin; 1:500 for 
SphK1) overnight. The membranes were washed with Tris buffered saline 
with 0.1% Tween-20 (TBST) three times and incubated with horseradish 
peroxide-conjugated goat anti rabbit secondary antibody for 1h. The 
immunoblots were developed using enhanced chemiluminescence detection 
system. The membranes were stripped with stripping buffer and incubated 
with β actin as internal control and developed. The optical density of the 







The technique of immunofluorescence was first described by Coons 
(Coons, 1960). Fluorescence is defined, based upon the physical definitions of 
the properties of the matter, as the ability to emit light without noticeable 
delay when irradiated. Fluorescence from untreated materials is known as 
primary or natural or self or auto fluorescence. When fluorescence is 
generated using additional fluorescent substances, it is known as secondary 
fluorescence. In secondary fluorescence, the first step involves the treatment 
of unlabelled antibody with the antigen in the sample to be tested. This is 
followed by the addition of a second flourochrome conjugated antibody, 
which reacts with the unlabelled antibody. This complex is then visualized 
using high sensitivity fluorescent microscopes.  
Cells are fixed to prevent the antibody from being bleached out during 
the experiment. Blocking is done to prevent nonspecific staining. The washing 




Poly lysine (P4707, Sigma, USA) 
Goat–anti-rabbit fluorochrome conjugated secondary antibody (AP132C, CY3 
or AQ132F, FITC Chemicon, Temecula, CA, USA) 
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Rabbit polyclonal SphK1 antibody (Abgent AP7237c, San Diego, USA) 
Rabbit TNF-α  antibody (Cell Signaling Technology 3707, Boston, MA, 
USA) 
FITC conjugated tomato (lycopersicom esculentum) Lectin (Sigma L0401, St. 
Louis, USA) 




Cover slips were sterilized and placed into 24 well plates. The cover 
slips were treated with poly lysine for 2 h at 4° C. BV2 cells were subcultured 
and grown in 10 % FBS medium overnight. The next day, the medium was 
discarded and the cells were washed with PBS twice. The cells were treated as 
per experimental requirements, then washed and fixed in 4 % 
paraformaldehyde for 30 min at 4° C. The cells were washed and blocked with 
normal goat serum at room temperature. The cells were then incubated with 
primary antibodies diluted in 5 % serum at recommended dilutions (1:100 for 
SphK1; 1:1000 for TNF-α) overnight at 4° C. The next day, the cells were 
washed 3 times for 10min each and incubated with the fluorochrome 
conjugated goat–anti-rabbit secondary antibody (1: 200, diluted in 5% Serum) 
at room temperature for 1h in the dark. Subsequently, the cells were 
counterstained with lectin (1:100), a commonly established marker for 
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microglia and incubated with DAPI (1:50,000) a nuclear marker, for 5 min at 
room temperature, washed, and mounted onto slides using fluorescent 
mounting medium. All steps were carried out in the dark. The slides were 
observed under confocal microscope (Olympus Fluoview 1000, Tokyo, 
Japan).  
2.6  siRNA gene silencing 
2.6.1 Principles 
 
Recent advances in molecular biology have shown that gene 
expression can be effectively silenced in a highly specific manner through the 
addition of double stranded RNA (dsRNA) (Fire, et al., 1998, Hannon, 2002, 
Napoli, et al., 1990). Individual genes can be silenced by interfering with 
mRNA transcription. This is done via a small double-stranded RNA.   An 
RNase III –like enzyme named DICER (Bernstein, et al., 2001) snips short 
interfering RNAs (siRNA) from longer double stranded RNAs made by either 
self-copying gene sequences, by replicating viruses, or by regulatory RNA 
sequences known as microRNAs.   All the double stranded RNAs are cleaved 
by DICER enzyme into short siRNA pieces that can suppress gene 
expression. The short siRNA pieces unwind into single strand RNAs, which 
then combine with proteins to form into a multi-subunit protein complex 
called RISC [RNA-Induced Silencing Complex] in an ATP dependent step 
(Nykanen, et al., 2001).  The RISC guides the siRNAs to the target RNA 
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sequence and then captures a native mRNA molecule that complements the 
short siRNA sequence. At some point the siRNA duplex unwinds, and it 
appears that the antisense strand remains bound to RISC and directs 
degradation of the complementary mRNA sequence by a combination of endo 
and exonucleases. If the pairing between native mRNA and siRNA piece is 
essentially perfect, the native mRNA is cut into unusable RNA fragments that 
cannot be translated.  If however, the pairing is less than perfect then the RISC 
complex binds to the mRNA and blocks ribosome movement along the native 
mRNA also halting translation. The net effect is that no protein is made. 
2.6.2 Materials 
 
predesigned siRNA (Ambion, CA, USA) 
OPTIMEM I reduced serum medium (31985, GIBCO, Invitrogen, USA) 
Oligofectamine (12252-011, Invitrogen, USA) 
siRNA Silencer® Select Negative Control siRNA (4390843, Ambion, CA, 
USA) 
2.6.3 siRNA sequences 
 





Table 3: siRNA sequences 
siRNA                         Sense                          Antisense 
    1.   
 
    2. 
 












2.6.4 Procedure for siRNA silencing of SphK1 
 
The BV2 cells were subcultured and plated onto 6 well plates at a 
density of 1x105 cells/ml. The total volume used per well was 2 ml. The cells 
were grown in DMEM with 10 % FBS without antibiotics for 24 h to achieve 
30-50% confluency of the cells. 10 µl of predesigned siRNA (50nm) with 100 
µl of OPTIMEM I reduced serum medium and 10 µl of Oligofectamine with 
100 µl of OPTIMEM were incubated at room temperature for 10 min 
separately. 100 µl per sample of the Oligofectamine + OPTIMEM medium 
was mixed with the siRNA mix, and incubated for 20 min at room 
temperature. The cells were washed and 800µl of OPTIMEM and 200µl of the 
final siRNA mix was added to per well and incubated for 8.5 h. 1ml of 10 % 
FBS in DMEM without antibiotics was added per well and then incubated for 
22 h. The transfected microglia were then treated with different combinations 
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(S1P, LPS, S1P+LPS) for the time points followed previously (30 min, 1 h, 3 
h, 6 h). The transfection conditions were optimized to obtain a suppression 
efficiency of more than 70-80%. The suppression efficiency was calculated by 
comparison with cells treated with scrambled (control) siRNA Silencer® 
Select Negative Control siRNA. 
2.7  ELISA 
2.7.1 Principles 
 
The cytokine ELISA (Enzyme-Linked Immunosorbent Assay) is a 
specific and highly sensitive method for quantitative measurements of 
cytokines or other analytes in solutions. A specific monoclonal antibody 
against the protein of interest (cytokine) is coated on a microtiter plate. A 
second monoclonal antibody, used for detection, binds to a different epitope 
on the protein. The secondary antibody is labeled with biotin, which allows 
subsequent binding of a Streptavidin conjugated enzyme. Any unbound 
reagents are washed away. When the substrate/chromophore 
Tetramethylbenzidine (TMB) is added, a color reaction will develop that is 
proportional to the amount of protein bound. The objective is to allow 
development of a color reaction through enzymic catalysis. The reaction is 
allowed to progress for a defined period after which the reaction is stopped by 
the alteration in pH (addition of H2SO4) of the system, or addition of an 
inhibiting reactant. Finally, the color is quantified by the use of a 
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spectrophotometer reading at the appropriate wavelength for the color 
produced. The concentration of protein is determined by comparison with a 
standard curve with known concentrations of protein. The detection limits for 
cytokine ELISAs are commonly in the lower picogram/ml range. 
2.7.2 Materials 
 
Mouse TNF-α ELISA kit (eBioscience; Cat #88-7324) 
2N H2SO4 (Sigma-Aldrich, Cat # 320501;  MO, USA) 
 
2.7.3 Procedure for TNF-α quantification by ELISA 
 
ELISA was carried out as per the instructions provided in the kit. 
NUNC Maxisorp 96 well ELISA plate was coated with 100 µl/well of capture 
antibody in coating buffer. The plate was sealed and incubated overnight at 4° 
C. The wells were aspirated and washed 5 times with >250 µl/well Wash 
Buffer, for 1min each time. The concentrated assay diluent was diluted with 4 
parts of distilled water and blocking was done with 200 µl/well of 1X assay 
diluent per well and incubated at room temperature for 1 h. The wells were 
aspirated and washed.  Recombinant TNF-α standard diluted in 1X assay 
diluent was added 100 µl/well of standard to the appropriate wells. 2-fold 
serial dilutions of the standards were done to make the standard curve.  100 
µl/well of the medium from the samples was added to the appropriate wells. 
The plate was covered and sealed and incubated overnight at 4° C for maximal 
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sensitivity. The wells were aspirated and washed for a total of 5 washes. 100 
µl/well of detection antibody diluted in 1X assay was added to each well. The 
plate was sealed and incubated at room temperature for 1 h. The wells were 
aspirated and washed. 100 µl/well of Avidin-HRP diluted in 1X assay diluent 
was added per well. The plate was sealed and incubated at room temperature 
for 30 minutes. The wells were aspirated and washed. 100 µl/well of 
Tetramethylbenzidine (TMB) Substrate Solution was added to each well. The 
plate was incubated at room temperature for 15 min. 50 µl of 2N H2SO4 stop 
solution was added to each well. The results were read using a microplate 
spectrophotometer at 450nm. The standard curve using TNF-α  standards was 
used to calculate the TNF-α production of the samples. 
2.8  Nitric Oxide Assay 
2.8.1 Principles 
 
Nitric oxide (NO) is oxidized to nitrite (NO2-) and nitrate (NO3-) in 
biological systems. Therefore, concentrations of these anions are used as a 
quantitative measure of NO production.  Nitrate is converted into nitrite 
utilizing nitrate reductase. Further addition of Griess reagents convert nitrite 
into a deep purple azo compound. Measurement of the absorbance of the azo 










The NO production was quantified colorimetrically using the nitric 
oxide colorimetric bioassay kit. NUNC Maxisorp 96 well plate was coated 
with 200 µl/well of diluted assay buffer. 80 µl/well of the supernatant 
collected from the differentially treated (LPS, S1P, LPS+S1P and siRNA) cell 
cultures were added to each well. 10 µl/well of the reconstituted enzyme 
cofactor mixture was added. 10 µl/well of the reconstituted nitrate reductase 
mixture was added subsequently to each well. The plate was covered and 
incubated at room temperature for 1-4h. 50µl/well of Griess reagent R1 was 
added per well and 50µl of Griess reagent R2 was added to each well 
immediately. Colour was allowed to develop for 10 min at room temperature 
and the absorbance was read using a microplate spectrophotometer at 540nm. 
The standard curve using nitrate standards was used to calculate the NO 

















Chapter 3: Results 
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3.1 SphK1 is expressed in microglial cells 
The protein and mRNA expression of SphK1 was detected in BV2 
microglial cells as revealed by the immunofluorescence (Fig. 1A-C) and PCR 
(Fig.1 D, E) analyses, respectively.  The SphK1-positive cells were confirmed 
to be microglia by colocalization with lectin (Fig.1 A-C). Western blot 
analysis also revealed that SphK1 was expressed in the microglial cells 
(Fig.2G).  
3.2 S1P receptors 1-5 are expressed in BV2 microglial 
cell line 
S1P acts intracellularly as a second messenger and extracellularly via 
G-protein coupled receptors, S1P1,2,3,4,5 (Ozaki, et al., 2003, Rosen and Goetzl, 
2005). PCR analysis showed that S1P receptors, S1P1,2,3,4,5  were expressed in 
BV2 cells (Fig.1E).  
3.3 Expression of SphK1 is increased in activated 
microglia 
SphK1 expression was increased in LPS-activated microglia. 
Immunofluorescence (IF) analysis showed the increase in SphK1 expression 
maximally at 1h after LPS treatment with a return to baseline levels at 6h post-
treatment (Fig.2A-F). This result was confirmed by the Western blot analysis 
which showed that the expression of SphK1 in activated microglia increased 
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significantly by 40%, at 1h post-treatment. However, the increase declined to 
base level by 6h post-treatment (Fig.2G-H). 
3.4 Suppression of SphK1 by DMS reduced the TNF-α 
production 
Effects of suppression of SphK1 by DMS on TNF-α production in 
LPS activated BV2 microglia were studied by IF and RT-PCR.  IF showed the 
increased expression of TNF-α  in microglia treated with LPS and this 
increase was attenuated by the DMS treatment (Fig 3A). Moreover, treatment 
of microglia with DMS alone also resulted in reduction of TNF-α expression 
compared to that of untreated samples. The real time RT-PCR analysis 
showed that LPS treatment increased the TNF-α mRNA expression in 
microglia but, upon concomitant suppression of SphK1 with DMS in LPS 
activated microglia, the level of TNF-α  mRNA expression was significantly 
reduced by 51% at 1h, 18% at 3h post treatment and was at par with LPS 
alone treatment at 6h (Fig.3B). Moreover, in microglia treated with DMS 
alone, TNF-α expression level appeared to be reduced or unaltered at different 
time points tested. 
3.5 Exogenous administration of S1P in BV2 microglia 
increased the TNF-α production 
The effects of administration of S1P on TNF-α expression in BV2 
cells was studied by IF and RT-PCR. IF showed increased expression of TNF-
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α  in microglia upon treatment with LPS or S1P (Fig.4 A-L). When S1P was 
administered in LPS activated BV2 microglia, the TNF-α expression was 
markedly increased compared to LPS alone treated samples (Fig. 4 D, H, L). 
The real time RT-PCR analysis showed a significant increase in the expression 
of TNF-α in microglia treated with S1P and LPS for 1h, 3h and 6h (Fig.4M). 
Upon addition of S1P to LPS activated microglia, the TNF-α  mRNA 
expression level was significantly increased by 126% at 1h post-treatment, 
compared to cells treated with S1P alone.  ELISA further confirmed that the 
exogenous administration of S1P increased the TNF-α  release in untreated 
and LPS-activated microglia. Moreover, the release of TNF-α  was found to 
be reduced significantly in untreated microglia and LPS-activated microglia 
with the suppression of SphK1 by DMS (Fig.4 N).   
3.6 Suppression of SphK1 by siRNA reduced TNF-α 
production in LPS activated microglia 
Immunofluorescence analysis showed that SphK1 immunoreactivity 
was markedly reduced in BV2 microglia transfected with SphK1 specific 
siRNA (SphK1-) compared to negative control cells (Fig 5 A, B). The siRNA 
transfection efficiency in BV2 microglia was found to be 80%, as revealed by 
real time RT-PCR (Fig.5C, D). Immunofluorescence analysis showed reduced 
expression of TNF-α  in SphK1- microglia, compared to cells transfected with 
negative control (Fig.5.E, F). However, administration of S1P increased the 
expression of TNF-α  in SphK1- cells treated with or without LPS (Fig 5 H, I). 
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Treatment of LPS alone was unable to increase the expression of TNF-α  in 
SphK1- microglial cells (Fig.5G).  The real time RT-PCR analysis showed that 
TNF-α mRNA expression was significantly silenced (80%) in SphK1- cells, 
compared to that in negative control (Fig.5J). LPS treatment was unable to 
increase TNFα expression in SphK1- cells compared to negative controls. 
However, treatment of S1P with or without LPS increased the expression of 
TNF-α by 20% in SphK1- cells, compared to that in negative control (Fig.5J). 
ELISA analysis confirmed that suppression of SphK1 with siRNA suppressed 
TNF-α production in untreated and LPS-treated microglia (Fig.5 K). 
However, exogenous administration of S1P with or without LPS increased 
TNF-α  production in SphK1- cells (Fig.5 K).  
3.7 Suppression of SphK1 by DMS reduced the mRNA 
expression level of IL-1β in BV2 microglia 
Effect of SphK1 suppression by DMS on IL-1β  mRNA expression in 
LPS-activated BV2 microglial cells was studied by the real time RT-PCR.  IL-
1β mRNA expression level was found to be reduced about 30% in microglia 
treated with DMS for 30min, compared to that of control (Fig.6B). LPS 
treatment increased IL-1β  mRNA expression but, upon concomitant 
suppression of SphK1 with DMS in LPS activated microglial cells, the 
expression level of IL-1β   was reduced significantly at 30min, 1h and 3h post-
treatment (Fig.6B). However, the reduction was not significant after 6h post-
treatment. 
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3.8 Exogenous administration of S1P in BV2 microglia 
increased the IL-1β mRNA expression  
The real time RT-PCR analysis showed that the IL-1β mRNA 
expression was increased significantly in BV2 microglial cells treated with 
LPS for 30min, 1h, 3h and 6h, compared to that of control. This increase in the 
expression level of IL-1β  was further augmented by the addition of S1P.The 
maximum increase in expression in cells treated with LPS and S1P was 
detected at 3h post-treatment (Fig.6C). Moreover, the significant increase of 
IL-1β mRNA expression level in microglia treated with S1P alone was 
detectable at 3h post-treatment. 
3.9 Suppression of SphK1 (SphK1-) by siRNA reduced 
IL-1β mRNA expression in LPS- activated 
microglia 
Real time RT-PCR analysis showed a significant decrease (40%) in the 
expression level of IL-1β in SphK1- microglia compared to that of negative 
control. LPS treatment was unable to increase IL-1β  mRNA expression in 
SphK1- cells compared to negative controls. However, S1P treatment (for the 
same duration as that of LPS) with and without LPS increased the expression 




3.10 SphK1 regulates the iNOS mRNA expression in 
activated BV2 microglia 
The real time RT-PCR analysis showed that LPS induced iNOS 
expression in BV2 cells at 6h post-treatment (Fig 7A, B). The LPS-induced 
increase in the iNOS expression in microglia was attenuated (20%) 
significantly by the concomitant suppression of SphK1 with DMS for 6h 
(Fig.7B). However, DMS was unable to alter the iNOS expression in activated 
BV2 cells significantly in early time points studied (data not shown).  
  LPS-induced iNOS mRNA expression in BV2 cells was further 
augmented significantly by the concomitant addition of S1P (Fig 7C).  
3.11 Suppression of SphK1 (SphK1-) by siRNA 
reduced the iNOS mRNA expression in LPS-
activated microglia.  
The real time RT-PCR analysis showed the significant suppression 
(82%) of iNOS expression in SphK1- microglia, compared with negative 
controls (Fig. 7D).  In addition, treatment of SphK1-cells with LPS, and S1P 
with or without LPS increased the iNOS expression compared to that observed 





3.12 SphK1 regulates NO production in BV2 microglial 
cells 
Nitric oxide assay showed the limited production of NO in SphK1- 
microglia treated with LPS and the increase in production of NO upon 
administration of SIP.  In SphK1- cells treated with LPS, the NO levels 
remained at baseline control levels (Fig.7E). However, exogenous 
administration of S1P with or without LPS increased NO  production in 













































Microglial activation is considered the hallmark of neuroinflammation. 
It is well established that activation of microglia in various neurodegenerative 
diseases and by exposing the cells to LPS, β-amyloid, thrombin, and IFN-
 γ experimentally enhances the release of large amounts of proinflammatory 
cytokines such as TNF-α and IL-1β and reactive oxygen intermediates such as 
ROS and NO, contributing to neuroinflammation and neurodegeneration 
(Block and Hong, 2005, Combs, et al., 2001, Dheen, et al., 2007, McCoy and 
Tansey, 2008, Vilhardt, 2005).  Hence,  determination of various mechanisms 
controlling microglial activation is believed to be an important step towards 
the suppression of neuroinflammation.  
Sphingolipids have been regarded as structural components of cell 
membranes until recently. Now it is well established that sphingomyelin 
hydrolysis produces ceramide generation, which can be then converted into 
ceramide-1-phosphate, sphingosine and sphingosine-1-phosphate.  SphK1, one 
of the enzymes involved in the sphingolipid metabolic pathway, is known to 
play a role in the activation of immune cells (Melendez, 2008), and is involved 
in TNF-α mediated inflammatory processes in immune cells (Hammad, et al., 
2008, Melendez, 2008). It has been reported that decreased levels of 
proinflammatory cytokines such as TNF-α and IL-1β are associated with 
inhibition of SphK1 (Maines, et al., 2008, Niwa, et al., 2000). These cytokines 
in CNS are largely produced by microglial cells in response to LPS, and are 
controlled by glucocorticoids (Allan and Rothwell, 2001, Nadeau and Rivest, 
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2002, Streit, et al., 1999). The chronic microglial reactivity and uncontrolled 
production of TNF-α and IL-1β are the direct causes of the neurodegeneration 
(Nadeau and Rivest, 2003, Streit, et al., 1999).   
Sphingolipids form a part of the phospholipids content in the CNS. 
High levels of sphingolipids are found in peripheral nerves and the white 
matter since it is a constituent of myelin sheaths (Sastry, 1985).  The present 
results have shown that microglia, the resident immune cells of the CNS, 
express SphK1. Since the presence of SphK1 was established in microglia, the 
next step was to find out which receptors of S1P were expressed in microglia 
since S1P would exert some of its many known actions via these receptors. 
The experiments showed that microglia express all the known five S1P 
receptors- S1P1, S1P2, S1P3, S1P4, S1P5. S1P1 activation is required for 
embryonic blood vessel development (Liu, et al., 2000). S1P2 and S1P3 play 
important roles in the number and survival of embryos in mice and hence are 
required for successful pregnancies (Ishii, et al., 2002). S1P4 is involved in T-
cell proliferation (Wang, et al., 2005). S1P5 is expressed in dendritic and 
natural killer cells (Walzer, et al., 2007). Since S1P receptor activation leads 
to such varied and diverse effects, studies in the future should establish which 
receptors are involved in the neurodegenerative pathway to give a better 
understanding of the mechanisms involved in microglial activation. 
 The study has further revealed that SphK1 expression is upregulated 
in LPS-activated microglia. Various other studies have shown similar 
upregulation of SphK1 in response to inflammatory stimuli. SphK1 promoter 
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was shown to be upregulated in response to LPS in RAW macrophages 
(Hammad, et al., 2006). Hypoxia inducible factor 2α has also been shown to 
upregulate SphK1 expression selectively in glial cells. Such upregulation of 
SphK1 in inflammatory conditions indicate that this maybe a proinflammatory 
mechanism and it leads to the generation of S1P. Hence the proinflammatory 
role of the sphingolipid pathway maybe attributed to S1P and the activation of 
specific S1P receptors since the S1P receptors seem to have conflicting roles 
as shown by other studies on neurons. S1P1 activation by S1P leads to Rac 
upregulation leading to neurite outgrowth (Estrach, et al., 2002). In contrast, 
when S1P2 is activated by S1P, it upregulates Rho which induces collapse of 
growth cones and inhibition of neurite outgrowth (Nakamura, et al., 2002), 
Therefore it is possible that the proinflammatory activity of sphingolipid 
pathway in microglia may be a result of the activation of a specific S1P 
receptor. Hence as mentioned earlier, it is essential in future studies to find out 
which S1P receptor is responsible for the proinflammatory effects. 
The study also shows concomitant increase in the release of TNF-
α  and  IL-1β  by activated microglia and therefore it is plausible that this 
effect is mediated via sphingolipid pathway, or that TNF-α  and  IL-1β 
activate the SphK1. Therefore we needed to confirm which came first in the 
sequence of events. For this, SphK1 would need to be inhibited first and then 
the microglia should be activated. The findings of this study show that the 
suppression of SphK1 activity in activated microglia by pretreatment of cells 
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with its inhibitor, DMS or transfection of cells with its siRNA, inhibited the 
expression levels of TNF-α, IL-1β and iNOS and release of TNF-α and NO. 
In addition, the BV2 microglial cells in the present study and purified 
microglia from primary cultures have been shown to express all or some of the 
five S1P receptors (Tham, et al., 2003). The results obtained clearly 
demonstrate that the sphingosine kinase signaling pathway is involved in 
inflammatory response of activated microglia in an autocrine/paracrine 
signaling fashion. 
The activated microglia in response to CNS inflammation secrete 
pro-inflammatory cytokines such as TNF-α and IL-1β (Carson, et al., 1998, 
Carson and Sutcliffe, 1999, Frei and Fontana, 1997, Hickey and Kimura, 
1988).  It is well known that pro-inflammatory factors such as TNF-α can 
participate in causation of neuronal death (Harry and Kraft, 2008, Harry, et al., 
2008, Kaushal and Schlichter, 2008). TNF signaling has been shown to have 
many functions such as regulation of BBB permeability, febrile responses, 
glutamatergic transmission and synaptic plasticity and scaling (McCoy and 
Tansey, 2008). Elevated levels of TNF-α are present in large number of 
neurological diseases such as ischemia, traumatic brain injury, multiple 
sclerosis, Alzheimer’s disease and Parkinsosn’s disease. Therefore modulation 
of TNF-α levels in neuroinflammatory conditions is an important method to 
delay the progression of these diseases. Activated microglia have also been 
known to express proinflammatory cytokines and chemokines such as IL-1β, 
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IL-8, IL-10, IL-12, etc (Dheen, 2007). This further suggests that S1P acts as 
an upstream factor via its receptors which induces the production of 
proinflammatory cytokines and neurotoxic substances such as NO in activated 
microglia. 
                The results also show that the exogenous addition of S1P could not 
restore the expression of cytokines completely in LPS activated SphK1- 
microglial cells although it enhanced the cytokine expression levels in 
untransfected LPS-treated BV2 cells. Since many of the biological responses 
of S1P are mediated via transactivation of S1P receptors (Anliker and Chun, 
2004, Spiegel and Milstien, 2003), the present results suggest that the 
exogenous addition of S1P in SphK1-microglial culture was not sufficient to 
induce the transactivation of S1P receptors and their downstream signaling 
pathways. Moreover, the elevated NO release in LPS-activated SphK1- 
microglial cells in response to exogenous S1P did not correlate with mRNA 
expression level of iNOS, which is responsible for the rapid production of NO. 
It is suggested that this discrepancy could be attributed to the differential NO 
production which may be regulated at the level of protein translation. 
The finding that the sphingosine signaling pathway is upregulated in 
activated microglia has important implications not only in inflammatory 
responses of microglial cells, but for other physiological and pathological 
processes regulated by S1P in neurons as it is a pleiotropic lipid mediator that 
regulates many different biological responses, including growth, survival, 
differentiation, cytoskeleton rearrangements, angiogenesis, vascular 
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maturation, and lymphocyte trafficking (Anliker and Chun, 2004, Olivera and 
Rivera, 2005, Olivera, et al., 2006, Rosen and Goetzl, 2005, Saba and Hla, 
2004, Spiegel and Milstien, 2003).  
The sphingosine signaling pathway has been implicated in 
neurodegenerative diseases such as Alzheimer’s disease. Although the 
pathogenesis of Alzheimer’s disease is not fully clear yet, it is understood that 
accumulation of β-amyloid causes neuronal degeneration and microglia 
activation. Studies in human neurons, oligodendrocytes and brain sections also 
provide direct evidence that β-amyloid causes sphingolipid pathway activation 
and ceramide accumulation (Okada, et al., 2009).  S1P plays a role in neuronal 
excitability since S1P2 null mice have spontaneous seizures and increase in 
excitatory currents (Okada, et al., 2009). These studies taken together with the 
results of this study suggest that the sphingolipid pathway in an important 
aspect in microglial and neuronal responses to inflammation in 
neurodegenerative diseases.  
4.1 Conclusion and scope for future study 
Neurodegenerative conditions such as Alzheimer’s disease and 
Parkinson’s disease cause immeasurable loss of treasured memories and 
debilitating physical symptoms.  Hence they captured wide attention and the 
need to find out possible cures or preventive strategies have gained urgency 
due to the increase in the lifespan of mankind, leading to an increase in the 
ageing population.  
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Microglial activation has been implicated as one of the key 
mechanisms in neurodegenerative conditions such as Alzheimer’s disease and 
Parkinson’s disease. Hence control and modulation of microglial activation is 
considered a viable means to achieve cure or control of these conditions. 
Therefore, the comprehensive effects of microglial modulation need to be 
studied to avoid any adverse effects. Recently the accumulation of the Aβ has 
been shown to cause neuronal degeneration in AD brains through abnormal 
sphingolipid metabolism (Okada, et al., 2009). It is well established that Aβ in 
AD brain activates microglia, which release large amounts of proinflammatory 
cytokines, and reactive oxygen intermediates, contributing to the 
neuroinflammation and neurodegeneration (Dheen, et al., 2005, Dheen, et al., 
2007). It is possible that this inflammatory response of microglia in the AD 
brain is mediated via S1P signaling pathway. 
The experimental results show that suppression of SphK1 activity 
thereby reducing S1P, in activated microglia leads to suppression of pro 
inflammatory cytokines and neurotoxic factors. This may be considered as a 
possible future therapeutic mode for the control of production of factors that 
contribute to neuroinflammation. However, the effects of suppression of 
SphK1 in microglia need to be carefully evaluated, as SphK1 is a known 
modulator of myriad other functions, not only in the CNS, but also other organ 
systems, and may cause undesirable side effects, if all the comprehensive 
effects are not taken into consideration. Hence, further studies need to be done 
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Fig.1 (A-C) Immunofluorescence shows the expression of SphK1 (red) in the 
cytoplasm of BV2 cells, double labeled with lectin (green). (D, E) RT-PCR 
analysis of cDNA derived from BV2 cells shows the expression of SphK1 
(507bp) and S1P receptors, S1P1,2,3,4,5  (80-120bp). Scale bar, 50µm. 
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Fig.2 (A-F) Immunofluorescence images showing changes in SphK1 
expression in microglia after treatment with LPS compared to untreated cells 
at 30min, 1 and 6h. The SphK1 expression peaks at 1h post treatment with 
LPS, but it returns to baseline levels at 6h. Western blot analysis (G, H) shows 
that the SphK1 protein expression increases after LPS treatment, and it 
reaches its maximum at 1h after treatment. The data represent the mean±SE of 
at least three independent experiments. Control vs LPS treated; *p<0.05. Scale 
bar (A), 50µm. 
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Fig.3 (A-L) Immunofluorescence images show that the TNF-α expression 
(green) is reduced with SphK1 suppression by DMS in LPS-treated BV2 cells 
at all time points (30min, 1h, 6h) when compared to cells treated with LPS 
alone. Note that LPS treatment gradually increases the TNF-α expression 
which peaks maximum at 6h in BV2 cells. (M, N) Real time RT-PCR analysis 
shows that TNF-α mRNA expression level is significantly increased in BV2 
cells treated with LPS for 30min, 1, 3, and 6h. The maximum increase is 
found 3h after the treatment. Suppression of SphK1 with DMS in LPS-treated 
BV2 cells results in a significant reduction in TNF-α mRNA expression 
compared with controls at all time points studied. The data represent the 
mean±SE of at least three independent experiments. The PCR product (205bp) 
for TNF-α is shown (M). Control vs DMS-treated; LPS-treated vs LPS+DMS-
treated; *p<0.05. Scale bar (A-L), 50µm. 
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Fig.4 S1P treatment increases TNF-α levels in BV2 cells. (A-L) 
Immunofluorescence images showing increased expression of TNF-α upon 
treatment with S1P. The TNF-α expression is increased noticeably when BV2 
cells are treated with S1P or LPS alone and S1P together with LPS. (M) RT-
PCR analysis shows the increased mRNA expression level of TNF-α in BV2 
cells treated with S1P or LPS or S1P+LPS at all time points studied (30min, 
1h, 3h, 6h), compared with untreated controls. (N) ELISA further confirms 
that the TNF-α release is increased in BV2 cells treated with S1P alone and 
S1P together with LPS and is reduced in cells treated with LPS+DMS.  The 
data shown are the mean±SE of at least three independent experiments. 

































Fig.5 Suppression of SphK1 (SphK1-) with siRNA reduces TNF-α production 
in BV2 microglial cells. (A, B) Immunofluorescence images show that SphK1 
immunoreactivity is markedly reduced in SphK1- cells compared to negative 
control cells. RT-PCR analysis shows that the efficiency of siRNA 
suppression of SphK1 is about 80% compared to negative controls (C). 
Crossing point of PCR cycles is also shown (D).  (E-I) Immunofluorescence 
images showing reduced expression of TNF-α in SphK1- cells. The TNF-α 
expression is reduced in SphK1- cells (F) but is increased with S1P 
administration (H). LPS treatment is unable to increase the expression of 
TNF-α  in SphK1- cells (G). However, the TNF-α expression is increased, 
when S1P is concomitantly administered with LPS in SphK1- cells (I). RT-
PCR (J) and ELISA (K) analyses shows that TNF-α mRNA expression and 
production are decreased in SphK1- cells respectively, compared with 
negative controls. LPS treatment is unable to increase TNF-α  mRNA 
expression and release in SphK1- cells. S1P treatment of SphK1- cells 
increases the production of TNF-α Upon treatment of SphK1- cells with S1P 
alone or S1P+LPS, the level of TNF-α  mRNA expression level and release is 
moderately increased above base negative control level (J), although there is 
no significant increase in its release (K). The data represent the mean±SE of at 
























Fig.6 RT-PCR analysis showing time-course plot of IL-1β mRNA expression 
in BV2 cells. (A) IL-1β (229bp) is amplified in BV2 microglial cells. (B) LPS 
treatment increases IL-1β expression at all time points studied but upon 
concomitant suppression of SphK1 with DMS in LPS activated cells, the IL1β 
expression is markedly reduced until 3h post treatment with a return to 
baseline levels at 6h. (C) IL-1β mRNA expression level is further increased 
significantly in LPS-treated cells upon addition of S1P, compared to cells 
treated with LPS alone. (D) RT-PCR analysis showing the suppression of IL-
1β mRNA expression in SphK1- cells. Suppression of SphK1 with siRNA 
results in a reduction in IL-1β mRNA expression compared with negative 
controls. LPS treatment is unable to increase IL-1β mRNA expression in 
SphK1- cells compared to negative controls. S1P treatment with or without 
LPS significantly increases the expression of IL-1β in SphK1- cells. The data 




































Fig.7 (A) RT PCR analysis showing suppression of SphK1 by DMS reduces 
iNOS mRNA expression in BV2 cells at different time points. (A) 217bp of 
iNOS PCR product is amplified. (B) LPS treatment increases iNOS expression 
in BV2 cells at 6h compared to control, but upon concomitant suppression of 
SphK1 with DMS in LPS activated cells, iNOS expression level is reduced 
significantly compared to cells treated with LPS alone. (C) RT-PCR analysis 
further shows that LPS-induced increase in iNOS mRNA expression in 
activated microglia is further augmented by the addition of S1P, compared to 
cells treated with LPS alone. (D) RT-PCR analysis shows that suppression of 
SphK1 with siRNA (SphK1-) decreases iNOS mRNA expression in BV2 
cells, compared with negative controls. Treatment of SphK1-cells with LPS, 
and S1P with or without LPS increases the iNOS expression compared to that 
observed in control SphK1-cells (D). However, this increase was not above 
that of negative control. (E) Nitric oxide assay shows that in SphK1- cells, the 
NO production is limited compared to negative control. In SphK1- cells 
treated with LPS, the NO levels remains at baseline control levels. However, 
exogenous administration of S1P with or without LPS increases NO 
production significantly in SphK1- cells.  The data represent the mean±SE of 
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